drug_type
RELEVANT_DRUG
intervention_type
Radiopharmaceutical (PSMA-targeted radioligand therapy)
drug_description
PSMA-targeted radioligand therapy: the small-molecule ligand PSMA-617 chelated to the beta-emitter lutetium-177; binds PSMA (FOLH1) on prostate cancer cells, is internalized, and delivers beta radiation causing DNA double-strand breaks with crossfire killing.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Lutetium Lu 177 Vipivotide Tetraxetan
drug_category
RADIOPEPTIDE CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
A PSMA-targeted small-molecule ligand (PSMA-617) chelated to lutetium-177 binds PSMA (FOLH1) on prostate cancer cells, is internalized, and emits beta particles that cause DNA double-strand breaks with a crossfire effect, leading to tumor cell death.
drug_name
[177Lu]Lu-PSMA-617
nct_id_drug_ref
NCT06388369